Today's Stocks Driving Success For The Health Care Sector

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 3 points (0.0%) at 15,545 as of Thursday, July 25, 2013, 12:49 PM ET. The NYSE advances/declines ratio sits at 1,346 issues advancing vs. 1,602 declining with 83 unchanged.

The Health Care sector currently sits up 0.5% versus the S&P 500, which is unchanged. Top gainers within the sector include Boston Scientific ( BSX), up 11.6%, Vertex Pharmaceuticals ( VRTX), up 2.5%, Amgen ( AMGN), up 1.9%, Celgene Corporation ( CELG), up 1.7% and Biogen Idec ( BIIB), up 1.4%. On the negative front, top decliners within the sector include Humana ( HUM), down 2.3%, Intuitive Surgical ( ISRG), down 2.5%, WellPoint ( WLP), down 1.7%, Bristol-Myers Squibb Company ( BMY), down 1.1% and Baxter International ( BAX), down 1.1%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. Alkermes ( ALKS) is one of the companies pushing the Health Care sector higher today. As of noon trading, Alkermes is up $1.51 (5.2%) to $30.68 on average volume. Thus far, 903,772 shares of Alkermes exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $29.00-$31.00 after having opened the day at $29.24 as compared to the previous trading day's close of $29.17.

Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. Alkermes has a market cap of $4.0 billion and is part of the drugs industry. Shares are up 59.3% year to date as of the close of trading on Wednesday. Currently there are 7 analysts that rate Alkermes a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Alkermes as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full Alkermes Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Shire ( SHPG) is up $5.55 (5.4%) to $108.07 on heavy volume. Thus far, 712,897 shares of Shire exchanged hands as compared to its average daily volume of 547,000 shares. The stock has ranged in price between $105.37-$109.06 after having opened the day at $105.80 as compared to the previous trading day's close of $102.52.

Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM). Shire has a market cap of $18.9 billion and is part of the drugs industry. Shares are up 11.2% year to date as of the close of trading on Wednesday. Currently there are 9 analysts that rate Shire a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Shire as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Shire Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Allergan ( AGN) is up $0.98 (1.1%) to $91.40 on light volume. Thus far, 649,738 shares of Allergan exchanged hands as compared to its average daily volume of 3.1 million shares. The stock has ranged in price between $90.49-$92.25 after having opened the day at $90.51 as compared to the previous trading day's close of $90.42.

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $26.9 billion and is part of the drugs industry. Shares are down 1.2% year to date as of the close of trading on Wednesday. Currently there are 11 analysts that rate Allergan a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Allergan Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home